Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
9.50
+0.08 (0.85%)
At close: Jan 17, 2025, 4:00 PM
9.55
+0.05 (0.53%)
Pre-market: Jan 21, 2025, 4:42 AM EST
Intellia Therapeutics Stock Forecast
NTLA's stock price has decreased by -64.5% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 16 analysts with 12-month price forecasts for NTLA stock have an average target of 53, with a low estimate of 12 and a high estimate of 120. The average target predicts an increase of 457.89% from the current stock price of 9.50.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for NTLA stock from 17 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 4 | 5 | 5 | 5 | 5 |
| Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Hold | 4 | 4 | 5 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 15 | 17 | 17 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Hold Maintains $20 → $12 | Hold | Maintains | $20 → $12 | +26.32% | Jan 14, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $60 → $40 | Buy | Maintains | $60 → $40 | +321.05% | Jan 13, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $70 → $60 | Buy | Maintains | $70 → $60 | +531.58% | Jan 10, 2025 |
| BMO Capital | BMO Capital | Buy Maintains $70 → $50 | Buy | Maintains | $70 → $50 | +426.32% | Jan 10, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $90 | Strong Buy | Maintains | $90 | +847.37% | Nov 19, 2024 |
Financial Forecast
Revenue This Year
55.32M
from 36.28M
Increased by 52.50%
Revenue Next Year
55.55M
from 55.32M
Increased by 0.42%
EPS This Year
-5.42
from -5.42
EPS Next Year
-5.60
from -5.42
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 83.8M | 220.5M | 166.3M | |||
| Avg | 55.3M | 55.6M | 67.0M | |||
| Low | 44.1M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 131.0% | 298.6% | 199.4% | |||
| Avg | 52.5% | 0.4% | 20.5% | |||
| Low | 21.6% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -5.10 | -4.35 | -3.91 | |||
| Avg | -5.42 | -5.60 | -5.73 | |||
| Low | -5.49 | -6.64 | -8.26 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.